Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Červinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F; VAYHIT2 Investigators.
Cuker A, et al.
N Engl J Med. 2026 Apr 16;394(15):1503-1513. doi: 10.1056/NEJMoa2515168. Epub 2025 Dec 9.
N Engl J Med. 2026.
PMID: 41363800
Clinical Trial.
Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line therapy in ITP. METHODS: In this phase 3, randomized, double-blind trial, we assigned, in a 1:1:1 ratio, adults with primary ITP and an insufficient response or a relapse af …
Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line therapy in ITP. METHODS: In this …